S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Abiomed Stock Forecast, Price & News

-11.80 (-3.49%)
(As of 11/26/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
207,453 shs
Average Volume
257,647 shs
Market Capitalization
$14.83 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Abiomed and its competitors with MarketBeat's FREE daily newsletter.

Abiomed logo

About Abiomed

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA.


Abiomed (NASDAQ:ABMD) Shares Gap Down to $361.71
November 8, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$847.52 million
Cash Flow
$5.33 per share
Book Value
$30.43 per share


Net Income
$225.52 million
Pretax Margin




Free Float
Market Cap
$14.83 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.21 out of 5 stars

Medical Sector

364th out of 1,391 stocks

Surgical & Medical Instruments Industry

41st out of 125 stocks

Analyst Opinion: 2.1Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -

Abiomed (NASDAQ:ABMD) Frequently Asked Questions

Is Abiomed a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abiomed in the last twelve months. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Abiomed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares.
View analyst ratings for Abiomed
or view top-rated stocks.

How has Abiomed's stock been impacted by Coronavirus (COVID-19)?

Abiomed's stock was trading at $151.13 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABMD stock has increased by 115.7% and is now trading at $325.98.
View which stocks have been most impacted by COVID-19

Are investors shorting Abiomed?

Abiomed saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 997,800 shares, an increase of 22.0% from the October 31st total of 817,700 shares. Based on an average daily volume of 205,300 shares, the short-interest ratio is presently 4.9 days. Approximately 2.2% of the company's stock are short sold.
View Abiomed's Short Interest

When is Abiomed's next earnings date?

Abiomed is scheduled to release its next quarterly earnings announcement on Thursday, January 27th 2022.
View our earnings forecast for Abiomed

How were Abiomed's earnings last quarter?

Abiomed, Inc. (NASDAQ:ABMD) announced its quarterly earnings results on Wednesday, October, 27th. The medical equipment provider reported $1.03 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.98 by $0.05. The medical equipment provider had revenue of $248.10 million for the quarter, compared to analyst estimates of $248.06 million. Abiomed had a trailing twelve-month return on equity of 15.80% and a net margin of 15.32%. The business's quarterly revenue was up 18.3% compared to the same quarter last year. During the same period last year, the business posted $1.01 EPS.
View Abiomed's earnings history

What guidance has Abiomed issued on next quarter's earnings?

Abiomed issued an update on its FY 2022 earnings guidance on Thursday, November, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.01 billion-$1.03 billion, compared to the consensus revenue estimate of $1.04 billion.

What price target have analysts set for ABMD?

4 brokers have issued 12 month price objectives for Abiomed's stock. Their forecasts range from $245.00 to $425.00. On average, they anticipate Abiomed's stock price to reach $363.75 in the next twelve months. This suggests a possible upside of 11.6% from the stock's current price.
View analysts' price targets for Abiomed
or view top-rated stocks among Wall Street analysts.

Who are Abiomed's key executives?

Abiomed's management team includes the following people:
  • Michael R. Minogue, Chairman, President & Chief Executive Officer (LinkedIn Profile)
  • David M. Weber, Chief Operating Officer & Senior Vice President
  • Todd A. Trapp, Chief Financial Officer & Vice President
  • Thorsten Sieß, Chief Technology Officer & Vice President
  • Charles A. Simonton, Chief Medical Officer

What is Michael R. Minogue's approval rating as Abiomed's CEO?

96 employees have rated Abiomed CEO Michael R. Minogue on Glassdoor.com. Michael R. Minogue has an approval rating of 72% among Abiomed's employees.

What other stocks do shareholders of Abiomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Square (SQ), Netflix (NFLX), Adobe (ADBE) and salesforce.com (CRM).

What is Abiomed's stock symbol?

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

Who are Abiomed's major shareholders?

Abiomed's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.46%), Baillie Gifford & Co. (8.23%), Wellington Management Group LLP (4.42%), Primecap Management Co. CA (3.96%), Renaissance Technologies LLC (3.44%) and Alliancebernstein L.P. (2.15%). Company insiders that own Abiomed stock include Andrew J Greenfield, Dorothy E Puhy, Joseph Riccelli, Magdalena Yesil, Martin P Sutter, Michael R Minogue, Michael R Minogue and Paul Thomas.
View institutional ownership trends for Abiomed

Which institutional investors are selling Abiomed stock?

ABMD stock was sold by a variety of institutional investors in the last quarter, including Villere ST Denis J & Co. LLC, Credit Suisse AG, Renaissance Technologies LLC, Wellington Management Group LLP, Primecap Management Co. CA, New York State Common Retirement Fund, Invesco Ltd., and SG Americas Securities LLC. Company insiders that have sold Abiomed company stock in the last year include Andrew J Greenfield, Joseph Riccelli, Magdalena Yesil, Martin P Sutter, Michael R Minogue, and Paul Thomas.
View insider buying and selling activity for Abiomed
or view top insider-selling stocks.

Which institutional investors are buying Abiomed stock?

ABMD stock was bought by a variety of institutional investors in the last quarter, including Marathon Asset Mgmt Ltd, Alliancebernstein L.P., Ownership Capital B.V., BlackRock Inc., Baillie Gifford & Co., Moors & Cabot Inc., PEAK6 Investments LLC, and Man Group plc.
View insider buying and selling activity for Abiomed
or or view top insider-buying stocks.

How do I buy shares of Abiomed?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abiomed's stock price today?

One share of ABMD stock can currently be purchased for approximately $325.98.

How much money does Abiomed make?

Abiomed has a market capitalization of $14.83 billion and generates $847.52 million in revenue each year. The medical equipment provider earns $225.52 million in net income (profit) each year or $3.24 on an earnings per share basis.

How many employees does Abiomed have?

Abiomed employs 1,725 workers across the globe.

Does Abiomed have any subsidiaries?

The following companies are subsidiares of Abiomed: ABD Holding Company, ABIOMED Athlone Ltd, ABIOMED Australia Pte. Ltd, ABIOMED Europe, ABIOMED Japan KK, ABIOMED Limited, ABIOMED R&D, ABIOMED SARL, ABIOMED Singapore Pte. Ltd, AIS GmbH Aachen Innovative Solutions, ECP Entwicklungsgesellschaft mbH, and Impella Cardiosystems.

When was Abiomed founded?

Abiomed was founded in 1981.

What is Abiomed's official website?

The official website for Abiomed is www.abiomed.com.

Where are Abiomed's headquarters?

Abiomed is headquartered at 22 CHERRY HILL DR, DANVERS MA, 01923.

How can I contact Abiomed?

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at (978) 646-1400, via email at [email protected], or via fax at 978-777-8411.

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.